AngioDynamics, Inc. (ANGO)

Over the past six months, AngioDynamics' stock price has fluctuated, decreasing by 12.8% since January 1st, 2026, but increasing by 14.29% in the past month. Key events include the Q3 2026 earnings report with net sales of $78.4 million, an 8.9% year-over-year increase, and a loss of ($0.07) per share, beating consensus estimates. Other events include Q2 and Q1 2026 earnings reports, a patent suit filed to protect its thrombectomy technology, analyst coverage with "buy" recommendations, and the upcoming retirement of CEO Jim Clemmer.

AngioDynamics experiences some demand seasonality. The first fiscal quarter has historically shown the highest utilization of cash due to incentive compensation and insurance payments. The fourth fiscal quarter is typically expected to generate substantial cash, consistent with historical seasonality.

AngioDynamics, Inc., headquartered in Latham, New York, is a medical technology company specializing in minimally invasive medical devices within the Medical sector and Health Care Equipment industry. The company's products aim to improve procedural outcomes, reduce complications, and enhance patient comfort. Its product portfolio focuses on vascular access, peripheral vascular intervention, and interventional oncology, including key products like the Auryon peripheral atherectomy platform and the AlphaVac mechanical thrombectomy system.

AngioDynamics markets its products in over 80 countries, utilizing direct sales teams and distribution partnerships across North America, Europe, Asia-Pacific, and Latin America. The company serves hospitals, specialty clinics, and physician offices.

AngioDynamics maintains a reputation as a medical technology company dedicated to improving patient outcomes through innovative vascular access and interventional oncology solutions. The company emphasizes its commitment to research and development, coupled with a robust regulatory and quality assurance framework. However, the company's stock performance has been described as volatile, and quarter-to-quarter performance has remained erratic and unpredictable, which could indirectly influence market perception.

AngioDynamics' ownership is primarily held by institutional investors, who collectively manage approximately 89.43% of the company's outstanding shares. Major institutional owners include BlackRock, Inc., Point72 Asset Management, L.P., Systematic Financial Management, L.P., The Vanguard Group, Inc., Bastion Asset Management Inc., and Dimensional Fund Advisors LP. Insiders own 5.35% of the company's stock.